KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $0.43.

  • Acadia Pharmaceuticals' EPS (Basic) rose 11500.0% to $0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.57, marking a year-over-year increase of 10128.21%. This contributed to the annual value of $1.37 for FY2024, which is 46526.68% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' EPS (Basic) is $0.43, which was up 11500.0% from $0.16 recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' EPS (Basic) registered a high of $0.87 during Q4 2024, and its lowest value of -$268.51 during Q4 2021.
  • In the last 5 years, Acadia Pharmaceuticals' EPS (Basic) had a median value of -$0.09 in 2021 and averaged -$14.15.
  • Per our database at Business Quant, Acadia Pharmaceuticals' EPS (Basic) crashed by 6383098.88% in 2021 and then surged by 190000.0% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' EPS (Basic) (Quarter) stood at -$268.51 in 2021, then skyrocketed by 99.9% to -$0.26 in 2022, then soared by 208.46% to $0.28 in 2023, then surged by 210.27% to $0.87 in 2024, then plummeted by 50.43% to $0.43 in 2025.
  • Its EPS (Basic) was $0.43 in Q3 2025, compared to $0.16 in Q2 2025 and $0.11 in Q1 2025.